

2021-2022 Campaign	VCH Quick Reference for COVID-19 Vaccines			
Available Vaccines	<i>MRNA COVID-19 VACCINES</i>		<i>VIRAL VECTOR-BASED VACCINES</i>	
	Pfizer-BioNTech	Moderna	AstraZeneca	COVISHIELD(SII)
Intended Population	16 years and older	18 years and older	30 years of age and older	30 years of age and older
Alternative Products and Interchangeability	<p align="center">DO NOT MISS AN IMMUNIZATION OPPORTUNITY</p> <p align="center"><i>AstraZeneca & COVISHIELD are interchangeable within the series however are not interchangeable with other COVID-19 vaccines (e.g. mRNA vaccines)</i></p> <p align="center"><i>Pfizer-BioNTech & Moderna mRNA vaccines may be interchangeable* however are not interchangeable with other COVID-19 vaccines (e.g. viral vector-based vaccines)</i></p>			
Dosage, Route, & Product Presentation**	<p align="center">0.3mL</p> <p align="center">Intramuscular injection; Multi dose vial (6 doses); 2-dose series</p>	<p align="center">0.5mL</p> <p align="center">Intramuscular injection; Multi dose vial (10 doses); 2-dose series</p>	<p align="center">0.5mL</p> <p align="center">Intramuscular injection; Multi dose vial (8 or 10 dose per vial) 2-dose series</p>	<p align="center">0.5mL</p> <p align="center">Intramuscular injection; Multi dose vial (10 doses) 2-dose series</p>
Product Preparation & Handling	<p align="center">Preservative-free. <i>Requires dilution with normal saline.</i></p>	<p align="center">Preservative-free. <i>No reconstitution required.</i></p>	<p align="center">Preservative-free. <i>No reconstitution required.</i></p>	<p align="center">Preservative-free. <i>No reconstitution required.</i></p>
Storage & expiry	<p align="center">Unused: Can be stored in ULT -80°C to -60°C for 6 months or -20°C to -15°C for up to 2 weeks or +2°C to +8°C for up to 5 days</p> <p align="center">After first puncture: can be stored at room temperature or refrigerator for up to 6 hours</p>	<p align="center">Unused: Can be stored at -25°C to -15°C for up to 6 months or +2°C to +8°C for up to 30 days</p> <p align="center">After first puncture: can be stored at room temperature or refrigerator for up to 6 hours</p>	<p align="center">Unused: Store between: +2°C to +8°C until expiry date</p> <p align="center">After first puncture: can be stored at room temperature for up to 6 hours, or 48 hours in a refrigerator (+2°C to +8°C). Total cumulative storage time up to 48 hours.</p>	<p align="center">Unused: Store between: +2°C to +8°C until expiry date</p> <p align="center">After first puncture: can be stored at room temperature for up to 6 hours, or 48 hours in a refrigerator (+2°C to +8°C). Total cumulative storage time up to 48 hours.</p>
Potential Allergens*** <i>No latex in any product</i>	Polyethylene glycol (PEG)	Polyethylene glycol (PEG)	Polysorbate 80	Polysorbate 80
Contraindications	<p>Applies to all COVID-19 vaccines:</p> <ul style="list-style-type: none"> History of anaphylactic reaction to any previous dose or any vaccine component Individuals who have had any allergic reaction < 4 hours of receiving dose #1, should not receive further doses until consultation with MHO is made or assessment by allergist Individuals with a history of anaphylaxis to tromethamine, should not be offered Moderna. Tromethamine may be present in contrast dyes; Individuals presenting with allergy to contrast dyes should preferentially be offered another COVID-19 vaccine. <ul style="list-style-type: none"> Severe allergy to Polyethylene glycol (PEG) [Pfizer-BioNTech and Moderna only] Severe allergy to Polysorbate 80 [AstraZeneca or COVISHIELD only] 			

**mRNA vaccines should be completed with the same mRNA COVID-19 vaccine product. If it is not possible to determine what product was used for the first dose, or if the same product is unavailable, the second dose may be given with an available mRNA product*

***AstraZeneca & COVISHIELD be can be re-refrigerated once punctured, but the cumulative storage time at room temperature must not exceed 6 hours, and the total cumulative storage time must not exceed 48 hours*

****PEG is commonly found in skin care products, cosmetics, cough syrup, laxatives, bowel preparation products for colonoscopy; Polysorbate 80 can be found in food, cosmetics, vitamin oils, anticancer meds*

VCH Clinical Recommendations and other COVID-19 Campaign Program Information

Special populations	<p>Though these populations were not included in the original vaccine trials, in the context of ongoing risk of COVID-19, the following individuals can be offered vaccination:</p> <ul style="list-style-type: none"> • Pregnant or breast-feeding women • Those with immunocompromising conditions or on medications that weaken their immune system • Those who have recently received any other immunization or a TB skin test
Suspension of AZ/SII products in adults 18 to 29 years of age	<p>Based on current evidence, NACI recommends the AstraZeneca/COVISHIELD vaccine may be offered to individuals 30 years of age and older with informed consent, if the individual does not wish to wait for an mRNA vaccine.</p> <p>Rare cases of serious blood clots and/or bleeding have been reported after receiving the vaccine (estimated to occur in approximately 1 in 100,000 vaccine recipients). The risk of severe COVID-19 infection is higher than the risk of serious blood clots and/or bleeding in places where there are high levels of COVID-19, but lower in places with less COVID-19 transmission. While the side effect is rare, it can be serious.</p> <p>Individuals receiving the AstraZeneca COVID-19 vaccine should be informed of this potential adverse event and advised to seek immediate medical attention if they develop signs and symptoms of thromboembolism and/or thrombocytopenia (eg. persistent headache beginning beyond 4 days after vaccination; seizure; difficulty moving part of your body; persistent blurry vision; difficulty speaking; SOB; chest pain; severe abdominal or back pain; new severe swelling, pain or color changes of an arm or leg; abnormal bruising or bleeding; reddish or purple spots or blood blisters under the skin) between days 4 and 28 following receipt of the AstraZeneca vaccine.</p>
Previous lab-confirmed COVID-19 infection	<p>Individuals who have had SARS-COV-2 infection are recommended to be immunized. Defer immunization to anyone who has been directed by Public Health to isolate as a case of COVID-19 or identified as a close contact (eg. currently on isolation/quarantine).</p>
Adverse Reactions	<p>ADVERSE REACTIONS: Mild to moderate side effects after vaccination are common, and expected.</p> <ul style="list-style-type: none"> • Individuals with history of only dermal allergic reaction (eg. erythema, pruritus, etc.) from 4-48 hours post vaccination, or non-urticarial rashes from 0-48 hours post vaccination can be immunized and need to be monitored for 30 minutes. • If an AEFI report has not already been submitted, the following events require a consult with a MHO prior to administration of dose 2: <ul style="list-style-type: none"> ○ Allergic or anaphylactic events ○ Neurologic events ○ Events that required medical attention or hospitalization after dose 1 ○ Events that were deemed by another health care provider to be a contraindication, precaution or a reason to postpone dose 2. • Report any adverse (unexpected reactions) to your local public health unit. To find out where to report see http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Forms/Immunization/Vaccine%20Info/adverse_event_map.pdf <p>If you have any questions, please consult with your clinic lead.</p>
Interval between vaccine doses (if applicable by product)	<p>A longer period between 2-dose series of 4 months will be observed (per NACI recommendations March 1, 2021). BC is maximizing the number of individuals benefiting from the first dose of vaccine. In general, regardless of the time between doses, interruption of a vaccine series does not require restarting the series.</p>
Extra doses from multi-dose vial	<p>When there is not enough vaccine for a full dose, a provider may pool from up to 3 separate vials from the same product and lot number to constitute a full additional dose (use as soon as possible to minimize the risk of bacterial growth and do not wait until end of day). Providers must only use residual volume to prepare a full dose when pooling vaccine (do not add contents from a vial that still contains a full dose).</p>
Continued PPE use following vaccination	<p>Vaccine recipients should continue to follow routine infection control practices and the recommended public health measures for prevention of SARS-COV-2 infection and transmission at this time.</p>
Immunizing during the COVID-19 Pandemic	<p>Vaccinators should wear a medical mask and eye protection as should other staff who are not able to maintain a two-metre physical distance (eg. Recovery room monitors and first aid providers). Vaccinators need not wear gloves, except when administering intranasal vaccine or oral vaccines (eg. Rotavirus) because of an increased likelihood of contact with a client's mucous membranes and bodily fluids during these procedures. If gloves are worn, they should be changed between clients and hand hygiene performed each time after gloves are removed.</p>